メインコンテンツにスキップ
検索

Conference: ISSX 2025 International Meeting

開催日: September 12 - 14, 2025

エリア:Chicago, Illinois

Discover the industry’s largest scientist-curated database for assessing drug interactions and safety

Trusted by 200+ pharmaceutical and biotech companies, as well as regulatory agencies, Certara’s Drug Interaction Database (DIDB®) provides unparalleled access to qualitative and quantitative human in vitro and clinical data. By incorporating information on extrinsic and intrinsic factors such as co-medications, excipients, food products, natural products, organ impairment, and genetics, DIDB® enables informed decision-making and supports the development of safer, more effective therapies.

Visit our booth for a demo of DIDB’s dynamic research tool’s and applications:

  • Retrieve information using 70+ pre-formulated queries
  • Optimize and validate PBPK models and static predictions
  • 医薬品ラベリングに関する推奨内容のサポート
  • Calculate clinical DDI risk using static prediction models and generate submission-ready reports
  • Quickly identify relevant concomitant medications
  • Gain insights beyond DDIs

Get an exclusive preview of DIDB’s ConMed Navigator

Built on regulatory agency-recommended classifications and powered by DIDB data, ConMed Navigator is scheduled to launch in Fall 2025. Sign up for a product demo to learn about how CoMed Navigator helps scientists to quickly identify concomitant medications.

Complete this form to schedule a DIDB product demo at ISSX 2025

薬物曝露をシミュレーション予測

Simcyp PBPK Simulatorは、医薬品開発におけるPBPKモデリングの業界標準として最も広く活用されているプラットフォームです。Developed through the expertise of a 25 year-long consortium involving 37 leading global pharmaceutical companies, the Simcyp PBPK Simulator is recognized and licensed by 11 regulatory agencies worldwide.

Ask our experts about your most complex DDI situations

With unique and multi-disciplinary expertise in DDIs, Certara’s Center of Excellence in Drug Interaction Science paves the way for leading experts across multiple teams to work in concert and solve event the most complex DDI scenarios form early development to regulatory approval.

Where to hear Certara insights and expertise

Sunday, September 21
Short Course 4: Model-informed drug discovery and development for challenging modalities

Co-chairs: Jaydeep Yadav, Merck; Fei Hua, Certara; Vivaswath Ayyar, GSK

  • FIH dose predictions for protein degraders with PKPD modelling – Jaydeep Yadav, Merck
  • Translational strategies for multi-specific antibodies (t-cell engagers) in oncology/immunology – Fei Hua, Certara
  • Modelling of oligonucleotides and RNAi therapeutics – Vivaswath Ayyar, GSK

Poster presentation

Pharmacokinetic Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2024: A Review of Clinical Data Available in New Drug Application Reviews

Presenting Author: Jingjing Yu, Director, Drug Interaction Solutions
Co-Author(s): Sophie Argon, Katie Owens, Yan Wang, Isabelle Ragueneau-Majlessi

In the present work, drug metabolism, drug transport, and drug interaction in vitro, in silico, and clinical data for small molecular drugs approved by the U.S. Food and Drug Administration in 2024 (N = 34) were analyzed using Certara Drug Interaction Database (DIDB®)

Get an exclusive preview of DIDB’s ConMed Navigator

Sign up for a sneak preview exclusive to ISSX 2025 attendees and learn about how CoMed Navigator helps scientists to quickly identify concomitant medications and more


Powered by Translations.com GlobalLink Web Software